Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.
暂无分享,去创建一个
Mark A. Hall | C. Dang | M. Fallahi | J. Cleveland | K. Unsal-Kaçmaz | A. Butler | J. Mishra | M. Cameron | W. Roush | A. Amelio | T. Bannister | Chunying Yang | R. Rounbehler | Weimin Li | J. Doherty | Kristen E. N. Scott | A. Hooper | M. Tortosa | K. G. Kumar | H. Genau | Fangzheng Li | Yunqi Lu | K. Scott
[1] Melania D’Angelosante. p. n. 6 , 2016 .
[2] M. Schwab,et al. DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome , 2013, Clinical Cancer Research.
[3] E. Giannoni,et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. , 2012, Cancer research.
[4] D. Green,et al. c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.
[5] Charles Y. Lin,et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.
[6] P. Blackshear,et al. Tristetraprolin Impairs Myc-Induced Lymphoma and Abolishes the Malignant State , 2012, Cell.
[7] Pierre J. Magistretti,et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration , 2012, Nature.
[8] M. Dewhirst,et al. Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis , 2012, PloS one.
[9] M. Casal,et al. Role of monocarboxylate transporters in human cancers: state of the art , 2012, Journal of Bioenergetics and Biomembranes.
[10] T. Kourelis,et al. Metformin and cancer: new applications for an old drug , 2012, Medical Oncology.
[11] Hongkai Ji,et al. Cell-Type Independent MYC Target Genes Reveal a Primordial Signature Involved in Biomass Accumulation , 2011, PloS one.
[12] J. Pouysségur,et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors , 2011, Proceedings of the National Academy of Sciences.
[13] Pierre Sonveaux,et al. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. , 2011, Cancer research.
[14] Johan Staaf,et al. GOBO: Gene Expression-Based Outcome for Breast Cancer Online , 2011, PloS one.
[15] M. Sola-Penna,et al. Lactate downregulates the glycolytic enzymes hexokinase and phosphofructokinase in diverse tissues from mice , 2011, FEBS letters.
[16] Hiroshi Tanaka,et al. MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer , 2010, International journal of cancer.
[17] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[18] G. Semenza,et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.
[19] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[20] R. Moreno-Sánchez,et al. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. , 2009, Mini reviews in medicinal chemistry.
[21] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[22] W. Gerald,et al. Genes that mediate breast cancer metastasis to the brain , 2009, Nature.
[23] Tsung-Cheng Chang,et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.
[24] Holger Sültmann,et al. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. , 2009, Lung cancer.
[25] T. Meshel,et al. Chemokines in human breast tumor cells: modifying their expression levels and determining their effects on the malignancy phenotype. , 2009, Methods in enzymology.
[26] Anthony Mancuso,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.
[27] Julien Verrax,et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. , 2008, The Journal of clinical investigation.
[28] Guido Kroemer,et al. Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.
[29] H. Shime,et al. Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway1 , 2008, The Journal of Immunology.
[30] M. Caligiuri,et al. A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents , 2008, Clinical Cancer Research.
[31] Tiago Costa Leite,et al. Lactate favours the dissociation of skeletal muscle 6-phosphofructo-1-kinase tetramers down-regulating the enzyme and muscle glycolysis. , 2007, The Biochemical journal.
[32] T. Potter,et al. Optimization of monocarboxylate transporter 1 blockers through analysis and modulation of atropisomer interconversion properties. , 2007, Journal of medicinal chemistry.
[33] W. Gerald,et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. , 2006, Cancer research.
[34] R. Spang,et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.
[35] A. Halestrap,et al. The Plasma Membrane Lactate Transporter MCT4, but Not MCT1, Is Up-regulated by Hypoxia through a HIF-1α-dependent Mechanism* , 2006, Journal of Biological Chemistry.
[36] A. Ross,et al. Monocarboxylate transporter MCT1 is a target for immunosuppression , 2005, Nature chemical biology.
[37] Ying Huang,et al. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. , 2005, Cancer research.
[38] J. Cleveland,et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. , 2005, Cancer cell.
[39] S. Schreiber,et al. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] Christopher H. Contag,et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.
[41] C. Turkington. Encyclopedia of Cancer , 2004 .
[42] D. Meredith,et al. The SLC16 gene family—from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond , 2004, Pflügers Archiv.
[43] John Eric Wilson. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function , 2003, Journal of Experimental Biology.
[44] Michael Q. Zhang,et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[45] Kenneth Chu,et al. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.
[46] P. Fernandez,et al. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.
[47] J. Massagué,et al. TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b , 2001, Nature Cell Biology.
[48] J. Massagué,et al. Repression of p15INK4b expression by Myc through association with Miz-1 , 2001, Nature Cell Biology.
[49] B. Kempkes,et al. Cell cycle activation by c‐myc in a Burkitt lymphoma model cell line , 2000, International journal of cancer.
[50] A. Barclay,et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression , 2000, The EMBO journal.
[51] C. Dang,et al. Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.
[52] O. Griffith,et al. Biologic and pharmacologic regulation of mammalian glutathione synthesis. , 1999, Free radical biology & medicine.
[53] M. Roussel,et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.
[54] N. Price,et al. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. , 1999, The Biochemical journal.
[55] R A Jungmann,et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[56] M. Poot,et al. Analysis of mitochondrial morphology and function with novel fixable fluorescent stains. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[57] J. Cleveland,et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.
[58] R. Eisenman,et al. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.
[59] M. Maekawa,et al. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. , 1988, Clinica chimica acta; international journal of clinical chemistry.
[60] L. Chen. Chapter 7 Fluorescent Labeling of Mitochondria , 1988 .
[61] R. Palmiter,et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.
[62] N. Kaplan,et al. Lactic Dehydrogenases: Functions of the Two Types , 1964 .
[63] N. Kaplan,et al. LACTIC DEHYDROGENASES: FUNCTIONS OF THE TWO TYPES RATES OF SYNTHESIS OF THE TWO MAJOR FORMS CAN BE CORRELATED WITH METABOLIC DIFFERENTIATION. , 1964, Science.
[64] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.